Filing Overview
Source discrepancy: The provided Form 10-Q is for Neuralstem, Inc., not Palisade Bio, Inc. It covers the quarter and nine months ended September 30, 2018, and was filed November 14, 2018. Neuralstem was a clinical-stage biopharmaceutical company developing neural stem-cell and small-molecule therapies for central nervous system diseases.
Business Context and Reporting Period
Neuralstem operated one business segment and had no commercial product revenue. Its lead programs included NSI-566 stem-cell therapy, NSI-189 small molecule therapy, and preclinical NSI-532 cell therapy. The company had five full-time employees as of October 31, 2018.
- NSI-566 Phase 2 ischemic-stroke trial initiated in China in August 2018.
- NSI-189 received FDA orphan designation for Angelman syndrome in August 2018.
- The prior NSI-189 Phase 2 major-depressive-disorder trial failed to meet its primary efficacy endpoint.
Financial Performance and Position
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | $2,500 in 2018 and 2017 | $257,500 in 2018 versus $7,500 in 2017 |
| Operating expenses | $2.1 million versus $2.6 million | $6.7 million versus $11.0 million |
| Operating loss | $2.1 million versus $2.6 million | $6.5 million versus $11.0 million |
| Net loss | $1.8 million versus $0.1 million | $4.6 million versus $12.4 million |
| Basic loss per share | $0.12 versus $0.01 | $0.30 versus $1.00 |
Revenue consisted primarily of intellectual-property license fees and, in the 2018 nine-month period, a $250,000 milestone-based royalty related to settlement of a prior patent infringement case. The company generated no revenue from sales of therapies.
- Research and development expense declined 35% year over year in the quarter and 55% for the nine-month period, primarily due to restructuring, lower personnel and facility costs, completion of the NSI-189 Phase 2 trial, increased grant reimbursements, and lower share-based compensation.
- General and administrative expense declined 2% in the quarter and 13% for the nine-month period.
- Other income included a noncash gain of $236,000 in the quarter and $1.8 million for the nine-month period from changes in the fair value of liability-classified warrants.
- Gross margin is not meaningful because revenue was minimal and the company was not operating a commercial product business.
Cash Flow, Debt and Liquidity
| Metric | Nine Months Ended September 30, 2018 | Nine Months Ended September 30, 2017 |
|---|---|---|
| Operating cash flow | $(6.0) million | $(11.1) million |
| Investing cash flow | $5.0 million | $(0.1) million |
| Financing cash flow | $0.1 million | $5.1 million |
| Ending cash and cash equivalents | $5.7 million | $9.1 million |
Cash and cash equivalents were $5.7 million at September 30, 2018, versus $6.7 million at December 31, 2017. The $5.0 million investing inflow reflected maturity of short-term investments. Current liabilities were $1.2 million, and warrant liabilities were $2.0 million. The filing does not present a material long-term debt balance at September 30, 2018, although the company had short-term borrowings and related financing obligations.
Management expected existing cash to fund operations into the second quarter of 2019. The company disclosed substantial doubt about its ability to continue as a going concern and stated that additional capital would be required.
Material Changes Versus the Prior Comparable Period
- Nine-month revenue increased by $250,000 due to a settlement-related milestone royalty, while recurring license-fee revenue remained $7,500.
- Nine-month operating expenses decreased $4.3 million, or 39%, and the net loss decreased $7.7 million.
- Operating cash use improved by $5.1 million, but the company remained dependent on external financing.
- Warrant-related accounting shifted from a $403,000 fair-value loss in 2017 to a $1.8 million fair-value gain in 2018, materially improving reported other income but not operating cash flow.
- The former CEO and CFO departed effective July 31, 2018. An interim CEO also served as principal accounting officer while a permanent management search continued.
- On October 29, 2018, after the reporting date, the company raised gross proceeds of $2.1 million through an offering of 3.0 million common shares and accompanying warrants, plus placement-agent warrants.
Guidance, Outlook, Risks and Unusual Items
- Management did not expect profitability in the next several years and anticipated additional operating losses.
- Additional equity or debt financing, grants, licensing arrangements, or collaborations were expected to be necessary; no future funding commitments existed.
- Failure to obtain financing could require delaying or eliminating clinical trials and research programs, curtailing operations, or seeking bankruptcy protection.
- Clinical and regulatory risk remained substantial: no product candidate had received marketing approval, and clinical results may not support future approval or commercialization.
- Key unusual items included the $250,000 settlement-related royalty, noncash warrant fair-value gains, SBIR grant reimbursements reducing research and development expense, and the October 2018 equity financing.
- Additional risks included potential NASDAQ minimum-bid noncompliance, dilution from future securities issuances and outstanding warrants, management turnover, reliance on third-party manufacturers and clinical providers, intellectual-property challenges, and limited operating resources.
Investor Verification Checklist
- Confirm the issuer identity: the supplied filing is Neuralstem, Inc., not Palisade Bio, Inc.
- Verify cash runway, the going-concern disclosure, and the terms and net proceeds of the October 2018 financing.
- Review warrant liabilities, approximately 3.9 million outstanding warrants, and potential dilution from options, warrants, and convertible preferred stock.
- Assess progress, enrollment, safety, and efficacy data for the NSI-566 stroke trial and other clinical programs.
- Evaluate the commercial implications of the failed NSI-189 depression trial and the absence of product revenue.
- Monitor management succession, NASDAQ listing compliance, and the company’s ability to secure additional capital.